Clinical trials: Specific Advanced Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
RATIONALE: 2-Methoxyestradiol may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of 2-methoxyestradiol in treating patients who have advanced solid tumors.
- Trial name
- NCT00030095
- Testing
- 2-methoxyestradiol
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal, Pancreatic
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V…
- Conditions
- Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT06767046
- Testing
- KRAS-specific Autologous TCR-T cell injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have…
- Trial name
- NCT00006456
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
RATIONALE: A computer-based survey and communication aid may help physicians and patients to communicate better and help make treatment decisions easier.
- Trial name
- NCT00244868
- Testing
- counseling intervention, educational intervention
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
This trial is studying the side effects and best dose of eribulin mesylate and cisplatin in treating patients with advanced solid tumors.Drugs used in chemotherapy, such as eribulin mesylate and cisplatin, work in different ways…
- Trial name
- NCT00415324
- Testing
- eribulin mesylate, cisplatin, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC).
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01383668
- Testing
- sirolimus, gold sodium thiomalate, pharmacological study
- Sponsor
- Mayo Clinic
Unspecified Adult Solid Tumor, Protocol Specific
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
This randomized phase I trial is studying the side effects and best dose of O(6)-benzylguanine when given together with ifosfamide and to see how well it works compared to ifosfamide alone in treating patients with unresectable…
- Trial name
- NCT00086970
- Testing
- ifosfamide, O6-benzylguanine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Unspecified Adult Solid Tumor, Protocol Specific
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid…
- Trial name
- NCT00004927
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Sponsor
- R-Pharm
Unspecified Adult Solid Tumor, Protocol Specific
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of alvocidib when given together with oxaliplatin, fluorouracil, and leucovorin calcium in treating patients with advanced solid tumors.
- Trial name
- NCT00080990
- Testing
- alvocidib, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts.
- Trial name
- NCT07700160
- Testing
- VBC108
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 230 people
- Sponsor
- VelaVigo Bio Inc
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in…
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00004241
- Testing
- tanespimycin, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Tri-specific Killer Engager, Solid Tumor
GTB-5550 in Advanced Solid Tumors
This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers.
- Conditions
- Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
- Trial name
- NCT07541573
- Testing
- GTB-5550
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Unspecified Adult Solid Tumor, Protocol Specific
GW786034 in Treating Patients With Advanced Solid Tumors
RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor.
- Trial name
- NCT00060151
- Testing
- pazopanib hydrochloride
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00253344
- Testing
- docetaxel, lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Solid Tumors
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy…
- Trial name
- NCT06741644
- Testing
- CS2009, Pemetrexed, Carboplatin
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 800 people
- Sponsor
- CStone Pharmaceuticals
Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- PTK/RAD (NCT00303732)
- Testing
- RAD001 (everolimus), PTK787 (vatalanib)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Daniel George, MD
Unspecified Adult Solid Tumor, Protocol Specific
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00052403
- Testing
- monoclonal antibody anti-anb3 integrin, anti-cytokine therapy, antiangiogenesis therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute